3-(4-fluoro-phenyl)-2-(6-methyl-pyridin-2-yl)-pyrazolo[1,5-a]pyridine-6-carboxylic acid (2-dimethylaminoethyl)-amide | 676344-30-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 3-(4-fluoro-phenyl)-2-(6-methyl-pyridin-2-yl)-pyrazolo[1,5-a]pyridine-6-carboxylic acid (2-dimethylaminoethyl)-amide
• 英文别名: 3-(4-Fluoro-phenyl)-2-(6-methyl-pyridin-2-yl)-pyrazolo[1,5-a]pyridine-6-carboxylic acid (2-dimethylamino-ethyl)-amide；N-[2-(dimethylamino)ethyl]-3-(4-fluorophenyl)-2-(6-methylpyridin-2-yl)pyrazolo[1,5-a]pyridine-6-carboxamide
• CAS: 676344-30-2
• 化学式: C₂₄H₂₄FN₅O
• 分子量: 417.486
• InChiKey: SVYLSRGWQBSDPO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  31
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.21
• 拓扑面积：
  62.5
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  3-(4-fluoro-phenyl)-2-(6-methyl-pyridin-2-yl)-pyrazolo[1,5-a]pyridine-6-carboxylic acid ethyl ester 、 N,N-二甲基乙二胺 在 dichloromethane hydrate 作用下， 反应 6.0h， 以to give 12 mg (10%) of the title compound MS ES+ m/e 418.2 (M+1)的产率得到3-(4-fluoro-phenyl)-2-(6-methyl-pyridin-2-yl)-pyrazolo[1,5-a]pyridine-6-carboxylic acid (2-dimethylaminoethyl)-amide
  参考文献：
  名称：

  Novel pyrazolopyridine derivatives as pharmaceutical agents

  摘要：

  本发明揭示了一种新型吡唑吡啶衍生物化合物，其作为药物代理使用，特别是其作为TGF-beta信号传导抑制剂在治疗癌症和其他受TGF beta影响的疾病状态中的应用。

  公开号：

  US20050222197A1

文献信息

• [EN] NOVEL PYRAZOLOPYRIDINE DERIVATVES AS PHARMACEUTICAL AGENTS<br/>[FR] DERIVES DE PYRAZOLOPYRIDINE TENANT LIEU D'AGENTS PHARMACEUTIQUES
  申请人：LILLY CO ELI

  公开号：WO2004026871A1

  公开（公告）日：2004-04-01

  Novel pyrazolopyridine derivative compounds are disclosed and their use as pharmaceutical agents, in particular their use as TGF-beta signal transduction inhibitors useful in the treatment of cancer and other disease states influenced by TGF beta.

  揭示了新型吡唑吡啶衍生物化合物及其作为药物代理的用途，特别是它们作为TGF-beta信号传导抑制剂在癌症和其他受TGF beta影响的疾病状态治疗中的用途。
• Pyrazolopyridine derivatives as pharmaceutical agents
  申请人：Eli Lilly and Company

  公开号：US07365066B2

  公开（公告）日：2008-04-29

  Novel pyrazolopyridine derivative compounds are disclosed and their use as pharmaceutical agents, in particular their use as TGF-beta signal transduction inhibitors useful in the treatment of cancer and other disease states influenced by TGF beta.

  本发明揭示了新型吡唑吡啶衍生物化合物，并且它们被用作制药剂，特别是用作TGF-beta信号传导抑制剂，可用于治疗受TGF beta影响的癌症和其他疾病状态。
• EFFICIENT INDUCTION OF PLURIPOTENT STEM CELLS USING SMALL MOLECULE COMPOUNDS
  申请人：Ichida Justin

  公开号：US20120021519A1

  公开（公告）日：2012-01-26

  The disclosure features a method of producing a reprogrammed cell (e.g. an induced pluripotent stem cell or an undifferentiated cell) from a differentiated (e.g. somatic) cell. In some embodiments, the methods includes contacting a differentiated (e.g. somatic cell) with a TGFBR1 inhibitor or anti-TGF-β-antibody to produce a reprogrammed cell (e.g. pluripotent stem cell or undifferentiated cell). Embodiments of the present invention relate to a reprogrammed cell and methods and compositions for producing a chemically produced reprogrammed cell or populations thereof.
• US7365066B2
  申请人：——

  公开号：US7365066B2

  公开（公告）日：2008-04-29